Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/190046
Title: | Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish primary cutaneous lymphoma registry |
Author: | Muniesa Montserrat, Cristina Gallardo, F. (Fernando) García-Doval, Ignacio Estrach Panella, Ma. Teresa (María Teresa) Combalia, Andrea Morillo, Mercedes De la Cruz-Vicente, Fátima Machan, Salma Moya-Martínez, Cristina Rovira, Roger Sanchez-Gonzalez, Blanca Acebo, Elvira Amutio, Elena Peñate, Yerai Losada-Castillo, Maria del Carmen Garcia-Muret, Maria P. Iznardo, Helena Román-Curto, Concepción Cañueto, Javier Fernández-de-Misa, Ricardo Flórez, Ángeles Izu, Rosa Torres-Navarro, Ignacio Zayas, Ana Pérez-Paredes, Gema Blanes, Mar Yanguas, J. Ignacio Pérez-Ferriols, Amparo Callejas-Charavia, Marta Ortiz-Romero, Pablo Luis Pérez Gil, Amalia Prieto-Torres, Lucia González Barca, Eva Servitje Bedate, Octavio |
Keywords: | Limfomes Cèl·lules T Quimioteràpia Lymphomas T cells Chemotherapy |
Issue Date: | 5-Aug-2022 |
Publisher: | Wiley |
Abstract: | Background: Brentuximab vedotin (BV) has been approved for CD30-expressing cutaneous T-cell lymphoma (CTCL) after at least one previous systemic treatment. However, real clinical practice is still limited. Objectives: To evaluate the response and tolerance of BV in a cohort of patients with CTCL. Methods: We analysed CTCL patients treated with BV from the Spanish Primary Cutaneous Lymphoma Registry (RELCP). Results: Sixty-seven patients were included. There were 26 females and the mean age at diagnosis was 59 years. Forty-eight were mycosis fungoides (MF), 7 Sézary syndrome (SS) and 12 CD30+ lymphoproliferative disorders (CD30 LPD). Mean follow-up was 18 months. Thirty patients (45%) showed at least 10% of CD30+ cells among the total lymphocytic infiltrate. The median number of BV infusions received was 7. The overall response rate (ORR) was 67% (63% in MF, 71% in SS and 84% in CD30 LPD). Ten of 14 patients with folliculotropic MF (FMF) achieved complete or partial response (ORR 71%). The median time to response was 2.8 months. During follow-up, 36 cases (54%) experienced cutaneous relapse or progression. The median progression free survival (PFS) was 10.3 months. The most frequent adverse event was peripheral neuropathy (PN) (57%), in most patients (85%), grades 1 or 2. Conclusions: These results confirm the efficacy and safety of BV in patients with advanced-stage MF, and CD30 LPD. In addition, patients with FMF and SS also showed a favourable response. Our data suggest that BV retreatment is effective in a proportion of cases. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1111/jdv.18563 |
It is part of: | Journal of the European Academy of Dermatology and Venereology, 2022 |
URI: | http://hdl.handle.net/2445/190046 |
Related resource: | https://doi.org/10.1111/jdv.18563 |
ISSN: | 0926-9959 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
725957.pdf | 213.97 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.